How vaccine hesitancy could impact the roll-out of the future COVID-19 vaccine

Podcast

Contemporary Pediatrics sat down with Andrew J. Schuman, MD, to discuss vaccine hesitancy and how those sentiments could impact the future COVID-19 vaccine.

Vaccine hesitancy and vaccine refusal have long been a problem in pediatrics. Last year's measles epidemic served as a signal of what the sentiments could mean for a disease that had been considered vanquished. What could they mean for COVID-19?

Contemporary Pediatrics sat down with Andrew J. Schuman, MD, to discuss vaccine hesitancy and how those sentiments could impact the future COVID-19 vaccine.

Recent Videos
Tina Tan, MD, comments on FDA expanded approval for MenQuadfi meningococcal disease vaccine
Tina Tan, MD, discusses impact of FDA's stricter COVID-19 vaccine policy for children
Jillian Cotter, MD
Decreasing antibiotics for acute otitis media and community acquired pneumonia, with Elysha Pifko, MD
Tina Tan, MD
Danielle Van Damme, DNP, CPNP-AC
Karen Y. Capusan, DNP, CPNP-PC
Measles outbreaks: 223 cases reported in Texas | Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN
Mary Koslap-Petraco, DNP, PPCNP-BC, CPNP, FAANP
Related Content
Weekly review: Clesrovimab for RSV approved, new dupilumab data, and more

Weekly review: Clesrovimab for RSV approved, new dupilumab data, and more

Joshua Fitch, Senior Editor
June 13th 2025
Article

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

What's going on with polio, monkeypox, and COVID-19

What's going on with polio, monkeypox, and COVID-19

Miranda Hester
August 19th 2022
Podcast

The news is full of stories about monkeypox, the recent changes to COVID-19 guidance, and the return of polio cases. What do clinicians need to know?

FDA expands glecaprevir/pibrentasvir indication for acute hepatitis C down to 3 years of age | Image credit: Contemporary Pediatrics

FDA expands glecaprevir/pibrentasvir indication for acute hepatitis C down to 3 years of age

Joshua Fitch, Senior Editor
June 12th 2025
Article

Glecaprevir/pibrentasvir was a "highly efficacious treatment for people with acute HCV," with 96.2% of patients analyzed having sustained virological response 12 weeks post-treatment.

What Omicron could mean for the pandemic

What Omicron could mean for the pandemic

Miranda Hester
January 7th 2022
Podcast

Contemporary Pediatrics sat down with Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, to discuss what's known about the variant. She also discusses the latest on the vaccine for children aged younger than 5 years.

Octavio Ramilo, MD, reacts to the FDA approval of clesrovimab for RSV prevention | Image Credit: St. Jude Children's Research Hospital

Octavio Ramilo, MD, reacts to the FDA approval of clesrovimab for RSV prevention

Octavio Ramilo, MD
June 10th 2025
Article

Ramilo, a clesrovimab clinical trial investigator, breaks down the recent FDA approval for the newest monoclonal antibody to protect against RSV disease in infants.

FDA approves clesrovimab to protect infants during first RSV season | Image Credit: Contemporary Pediatrics

FDA approves clesrovimab to protect infants during first RSV season

Joshua Fitch, Senior Editor
June 9th 2025
Article

The BLA for clesrovimab was based on results demonstrated in the phase 2b/3 CLEVER trial among healthy pre-term and full-term infants.

© 2025 MJH Life Sciences

All rights reserved.